The pharmaceutical industry is well past the time when licensing was seen as merely a supplement to the internal R&D program. Now, it often plays a more important role than the company's internal R&D. As dealmaking becomes a bigger part of the overall pipeline building program, investors will require greater clarity from companies who now can bury external dealmaking costs in one-time write-offs or aggregated clash flow numbers.
by Roger Longman
The industry is now well past the time when licensing was a corporate backstop, seen as a mere supplement to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
